The drug vehicle and solvent N-Methylpyrrolidone is an immunomodulator and antimyeloma compound

Cell Reports

Volumn 7, Issue 4, 2014, Pages 1009-1019

  Shortt, Jake ^a,b   Hsu, Andy K ^a,b   Martin, Benjamin P ^a,b   Doggett, Karen ^b   Matthews, Geoffrey M ^a,b   Doyle, Maria A ^a,b   Ellul, Jason ^a,b   Jockel, Tina E ^a,b   Andrews, Daniel M ^a,b   Hogg, Simon J ^a,b   Reitsma, Andrea ^a,b   Faulkner, David ^a,b   Bergsagel, P Leif ^c   Chesi, Marta ^c   Heath, Joan K ^b   Denny, William A ^d   Thompson, Philip E ^e   Neeson, Paul J ^a,b   Ritchie, David S ^a,b   McArthur, Grant A ^a,b   Johnstone, Ricky W ^a,b   more..

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF AUCKLAND   (New Zealand)

^e MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL 2 PYRROLIDINONE; ACETYLLYSINE MIMETIC; ANTIMYELOMA COMPOUND; ANTINEOPLASTIC AGENT; BROMODOMAIN AND EXTRATERMINAL DOMAIN PROTEIN; BROMODOMAIN AND EXTRATERMINAL DOMAIN PROTEIN INHIBITOR; CEREBLON; CHEMICAL COMPOUND; DIMETHYL SULFOXIDE; DRUG VEHICLE; IKAROS 1; IKAROS 3; IKAROS TRANSCRIPTION FACTOR; IMMUNOMODULATING AGENT; IMMUNOMODULATORY THALIDOMIDE ANALOG; JQ 1; LENALIDOMIDE; LYSINE DERIVATIVE; N ACETYLLYSINE; PROTEIN; PROTEIN INHIBITOR; SOLVENT; UNCLASSIFIED DRUG; BET PROTEIN; CEREBLON PROTEIN; INTERFERON REGULATORY FACTOR 4; MYC PROTEIN; ONCOPROTEIN; TRANSCRIPTION FACTOR; 2 PYRROLIDONE DERIVATIVE; IMMUNOLOGIC FACTOR; N-METHYLPYRROLIDONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIMYELOMA ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EXPOSURE; DRUG STRUCTURE; IMMUNOMODULATION; MOUSE; MYELOMA; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE C MYC; PRIORITY JOURNAL; TUMOR MODEL; ANIMAL MODEL; BIOLOGICAL ACTIVITY; DOSE RESPONSE; DOWN REGULATION; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG TARGETING; HUMAN; HUMAN CELL; PHENOTYPIC VARIATION; TRANSCRIPTION REGULATION; ANIMAL; C57BL MOUSE; CELL CULTURE; CELL DIFFERENTIATION; DRUG EFFECTS; DRUG SCREENING; IMMUNOLOGY; METABOLISM; MULTIPLE MYELOMA; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; CELLS, CULTURED; HUMANS; IMMUNOLOGIC FACTORS; MICE; MICE, INBRED C57BL; MULTIPLE MYELOMA; PYRROLIDINONES; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84901248465     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2014.04.008     Document Type: Article

References (40)

1. Abouelfadel Z., Crawford E.D. Leuprorelin depot injection: patient considerations in the management of prostatic cancer. Ther. Clin. Risk Manag. 2008, 4:513-526.
2. Akesson B. N-Methyl-2-pyrrolidone. Concise international chemical assessment document 35, N-Methyl-2-pyrrolidone. International Programme on Chemical Safety and Inter-Organization Programme for the Sound Management of Chemicals 2001, World Health Organisation, Geneva.
3. Akesson B., Carnerup M.A., Jönsson B.A. Evaluation of exposure biomarkers from percutaneous absorption of N-methyl-2-pyrrolidone. Scand. J. Work Environ. Health 2004, 30:306-312.
4. Belkina A.C., Nikolajczyk B.S., Denis G.V. BET protein function is required for inflammation: Brd2 genetic disruption and BET inhibitor JQ1 impair mouse macrophage inflammatory responses. J. Immunol. 2013, 190:3670-3678.
5. Carnerup M.A., Saillenfait A.M., Jönsson B.A. Concentrations of N-methyl-2-pyrrolidone (NMP) and its metabolites in plasma and urine following oral administration of NMP to rats. Food Chem. Toxicol. 2005, 43:1441-1447.
6. Chaiyachati B.H., Jani A., Wan Y., Huang H., Flavell R., Chi T. BRG1-mediated immune tolerance: facilitation of Treg activation and partial independence of chromatin remodelling. EMBO J. 2013, 32:395-408.
7. Chapuy B., McKeown M.R., Lin C.Y., Monti S., Roemer M.G., Qi J., Rahl P.B., Sun H.H., Yeda K.T., Doench J.G., et al. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer Cell 2013, 24:777-790.
8. Chesi M., Matthews G.M., Garbitt V.M., Palmer S.E., Shortt J., Lefebure M., Stewart A.K., Johnstone R.W., Bergsagel P.L. Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. Blood 2012, 120:376-385.
9. Davies F.E., Raje N., Hideshima T., Lentzsch S., Young G., Tai Y.T., Lin B., Podar K., Gupta D., Chauhan D., et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001, 98:210-216.
10. Delmore J.E., Issa G.C., Lemieux M.E., Rahl P.B., Shi J., Jacobs H.M., Kastritis E., Gilpatrick T., Paranal R.M., Qi J., et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011, 146:904-917.
11. Filippakopoulos P., Qi J., Picaud S., Shen Y., Smith W.B., Fedorov O., Morse E.M., Keates T., Hickman T.T., Felletar I., et al. Selective inhibition of BET bromodomains. Nature 2010, 468:1067-1073.
12. Filippakopoulos P., Picaud S., Mangos M., Keates T., Lambert J.P., Barsyte-Lovejoy D., Felletar I., Volkmer R., Müller S., Pawson T., et al. Histone recognition and large-scale structural analysis of the human bromodomain family. Cell 2012, 149:214-231.
13. Gandhi A.K., Kang J., Havens C.G., Conklin T., Ning Y., Wu L., Ito T., Ando H., Waldman M.F., Thakurta A., et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.). Br. J. Haematol. 2014, 164:811-821.
14. Haslett P.A., Corral L.G., Albert M., Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J. Exp. Med. 1998, 187:1885-1892.
15. Hewings D.S., Wang M., Philpott M., Fedorov O., Uttarkar S., Filippakopoulos P., Picaud S., Vuppusetty C., Marsden B., Knapp S., et al. 3,5-dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands. J. Med. Chem. 2011, 54:6761-6770.
16. Hou L.T., Yan J.J., Tsai A.Y., Lao C.S., Lin S.J., Liu C.M. Polymer-assisted regeneration therapy with Atrisorb barriers in human periodontal intrabony defects. J. Clin. Periodontol. 2004, 31:68-74.
17. Hsu A.K., Quach H., Tai T., Prince H.M., Harrison S.J., Trapani J.A., Smyth M.J., Neeson P., Ritchie D.S. The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood 2011, 117:1605-1613.
18. Huang R., Xia M., Cho M.H., Sakamuru S., Shinn P., Houck K.A., Dix D.J., Judson R.S., Witt K.L., Kavlock R.J., et al. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ. Health Perspect. 2011, 119:1142-1148.
19. Ito T., Ando H., Suzuki T., Ogura T., Hotta K., Imamura Y., Yamaguchi Y., Handa H. Identification of a primary target of thalidomide teratogenicity. Science 2010, 327:1345-1350.
20. Jouyban A., Fakhree M.A., Shayanfar A. Review of pharmaceutical applications of N-methyl-2-pyrrolidone. J. Pharm. Pharm. Sci. 2010, 13:524-535.
21. Krönke J., Udeshi N.D., Narla A., Grauman P., Hurst S.N., McConkey M., Svinkina T., Heckl D., Comer E., Li X., et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 2014, 343:301-305.
22. Lee P.J., Langer R., Shastri V.P. Role of n-methyl pyrrolidone in the enhancement of aqueous phase transdermal transport. J. Pharm. Sci. 2005, 94:912-917.
23. Lodé L., Amiot M., Maiga S., Touzeau C., Menard A., Magrangeas F., Minvielle S., Pellat-Deceunynck C., Bene M.C., Moreau P. Cereblon expression in multiple myeloma: not ready for prime time. Br. J. Haematol. 2013, 163:282-284.
24. Lopez-Girona A., Mendy D., Ito T., Miller K., Gandhi A.K., Kang J., Karasawa S., Carmel G., Jackson P., Abbasian M., et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 2012, 26:2326-2335.
25. Lu G., Middleton R.E., Sun H., Naniong M., Ott C.J., Mitsiades C.S., Wong K.K., Bradner J.E., Kaelin W.G. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 2014, 343:305-309.
26. *MYC multiple myeloma. Cell Death Dis. 2013, 4:e798.
27. Miguel B.S., Ghayor C., Ehrbar M., Jung R.E., Zwahlen R.A., Hortschansky P., Schmoekel H.G., Weber F.E. N-methyl pyrrolidone as a potent bone morphogenetic protein enhancer for bone tissue regeneration. Tissue Eng. Part A 2009, 15:2955-2963.
28. Moreira A.L., Sampaio E.P., Zmuidzinas A., Frindt P., Smith K.A., Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J. Exp. Med. 1993, 177:1675-1680.
29. Nicodeme E., Jeffrey K.L., Schaefer U., Beinke S., Dewell S., Chung C.W., Chandwani R., Marazzi I., Wilson P., Coste H., et al. Suppression of inflammation by a synthetic histone mimic. Nature 2010, 468:1119-1123.
30. Philpott M., Yang J., Tumber T., Fedorov O., Uttarkar S., Filippakopoulos P., Picaud S., Keates T., Felletar I., Ciulli A., et al. Bromodomain-peptide displacement assays for interactome mapping and inhibitor discovery. Mol. Biosyst. 2011, 7:2899-2908.
31. Puissant A., Frumm S.M., Alexe G., Bassil C.F., Qi J., Chanthery Y.H., Nekritz E.A., Zeid R., Gustafson W.C., Greninger P., et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov. 2013, 3:308-323.
32. Ramirez-Carrozzi V.R., Nazarian A.A., Li C.C., Gore S.L., Sridharan R., Imbalzano A.N., Smale S.T. Selective and antagonistic functions of SWI/SNF and Mi-2β nucleosome remodeling complexes during an inflammatory response. Genes Dev. 2006, 20:282-296.
33. Saillenfait A.M., Sabaté J.P., Gallissot F. Comparative developmental toxicities of the three major metabolites of N-methyl-2-pyrrolidone after oral administration in rats. J. Appl. Toxicol. 2007, 27:571-581.
34. Shaffer A.L., Emre N.C., Lamy L., Ngo V.N., Wright G., Xiao W., Powell J., Dave S., Yu X., Zhao H., et al. IRF4 addiction in multiple myeloma. Nature 2008, 454:226-231.
35. Shortt J., Hsu A.K., Johnstone R.W. Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy. Oncogene 2013, 32:4191-4202.
36. Shortt J., Martin B.P., Newbold A., Hannan K.M., Devlin J.R., Baker A.J., Ralli R., Cullinane C., Schmitt C.A., Reimann M., et al. Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas. Blood 2013, 121:2964-2974.
37. Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., Paulovich A., Pomeroy S.L., Golub T.R., Lander E.S., Mesirov J.P. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 2005, 102:15545-15550.
38. Vidler L.R., Brown N., Knapp S., Hoelder S. Druggability analysis and structural classification of bromodomain acetyl-lysine binding sites. J. Med. Chem. 2012, 55:7346-7359.
39. Wu D., Smyth G.K. Camera: a competitive gene set test accounting for inter-gene correlation. Nucleic Acids Res. 2012, 40:e133.
40. Zhu Y.X., Braggio E., Shi C.X., Bruins L.A., Schmidt J.E., Van Wier S., Chang X.B., Bjorklund C.C., Fonseca R., Bergsagel P.L., et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 2011, 118:4771-4779.